# BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment

> **NCT00632749** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 68 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** BI 811283 (d 1 and 15)
- **DRUG:** Cytarabine
- **DRUG:** BI 811283 (d1)
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT00632749
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-05
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2015-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00632749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00632749, "BI 811283 in Combination With Cytarabine in Previously Untreated AML Ineligible for Intensive Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00632749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*